Bristol Myers Squibb Co: management transactions · United States · SEC (Form 4)

About Bristol Myers Squibb Co

Bristol Myers Squibb Co. (NYSE: BMY) is a major U.S.-based biopharmaceutical company headquartered in Princeton, New Jersey, United States. Its roots date back to 1887, when William Bristol and John Myers acquired Clinton Pharmaceutical Company; over time, the business evolved through major corporate combinations, including the Squibb heritage, into one of the best-known names in global pharmaceuticals. For international investors, BMS stands out as a company that combines large, cash-generative legacy franchises with an innovation-led pipeline focused on serious diseases. ([bms.com](https://www.bms.com/about-us/our-company/history-timeline.html?utm_source=openai)) The company discovers, develops, manufactures and commercializes therapies across several important therapeutic areas, with particular strength in oncology, hematology, immunology, and cardiovascular disease. Its core portfolio includes blockbuster and specialist brands such as Opdivo, Eliquis, Revlimid, Camzyos, Breyanzi, Reblozyl, Opdualag, Yervoy, Orencia, Sotyktu and Zeposia. That mix is important from an equity-analysis perspective because it combines mature assets that still produce substantial revenue with newer products designed to offset patent expiries and generic erosion. ([bms.com](https://www.bms.com/media/media-library/key-facts.html?utm_source=openai)) Competitively, Bristol Myers Squibb ranks among the leading global innovative pharma companies. It competes with large multinational peers across different therapeutic segments, but it has especially deep positioning in immuno-oncology and selected cardiovascular treatments. At the same time, the company remains exposed to generic competition on older products, which makes the strength of its pipeline, clinical execution and business-development strategy central to the investment case. In its 2025 full-year results, BMS reported revenue of $48.2 billion and guided to 2026 revenue of approximately $46.0 billion to $47.5 billion, underscoring the scale of the business while also reflecting ongoing portfolio transition dynamics. ([bms.com](https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_financials/quarterly_reports/2025/BMY-Q4-2025-Earnings-Press-Release.pdf)) BMS has a broad global footprint, with sales in the United States and international markets, and a worldwide network of research, development and commercial operations. Recent headlines highlight an active pipeline and continued strategic investment: in February 2026, the FDA accepted the NDA for iberdomide in relapsed/refractory multiple myeloma; in May 2026, BMS announced a strategic collaboration with Hengrui Pharma covering 13 early-stage programs in oncology, hematology and immunology; and during the first half of 2026 the company reported positive Camzyos data as well as expanded Opdivo approvals in classical Hodgkin lymphoma. For equity investors, these developments reinforce BMS’s thesis as a diversified large-cap biopharma company whose medium-term upside depends on successful launches, label expansion and pipeline conversion. ([investors.bms.com](https://investors.bms.com/iframes/press-releases/press-release-details/2026/U-S--Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-New-Drug-Application-for-Iberdomide-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma/default.aspx?utm_source=openai))